1. Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study by Franco Dammacco, Felicia Anna Tucci, Gianfranco Lauletta, Pietro Gatti, Valli De Re, Vincenza Conteduca, Silvia Sansonno, Sabino Russi, Maria Addolorata Mariggiò, Maria Chironna, and Domenico Sansonno Blood Volume 116(3):343-353 July 22, 2010 ©2010 by American Society of Hematology

2. Design of PIRR schedule. Franco Dammacco et al. Blood 2010;116:343-353 ©2010 by American Society of Hematology

3. Probability of complete response during PIRR and combination therapies. Franco Dammacco et al. Blood 2010;116:343-353 ©2010 by American Society of Hematology

4. Response maintenance after PIRR and Peg-IFNα/RBV schedules. Franco Dammacco et al. Blood 2010;116:343-353 ©2010 by American Society of Hematology

5. Chronologic relationships among cutaneous vasculitis, viral load (HCV RNA), cryocrit percentage, serum C4 level, and B-cell clonalities in a representative patient (male, 61 years) who relapsed. Franco Dammacco et al. Blood 2010;116:343-353 ©2010 by American Society of Hematology

6. Low (20×/0.40) and high (63×/0.75) magnification of liver histology before PIRR therapy and after the follow-up period from a responsive MC patient (female, 59 years). Franco Dammacco et al. Blood 2010;116:343-353 ©2010 by American Society of Hematology